Receipt: https://pmc.ncbi.nlm.nih.gov/articles/PMC5876407/ Read: 2026-11-12, curl with browser user agent, HTML converted to text, HTTP 200 Note: Randomized crossover trial of oral NR, an NAD+ precursor. (Text converted from HTML; the superscript plus in NAD+ is joined to the word.) --- Abstract Nicotinamide adenine dinucleotide (NAD+) has emerged as a critical co-substrate for enzymes involved in the beneficial effects of regular calorie restriction on healthspan. As such, the use of NAD+ precursors to augment NAD+ bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging in humans. Here we provide the evidence in a 2 × 6-week randomized, double-blind, placebo-controlled, crossover clinical trial that chronic supplementation with the NAD+ precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD+ metabolism in healthy middle-aged and older adults. Our results also provide initial insight into the effects of chronic NR supplementation on physiological function in humans, and suggest that, in particular, future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group. Declining NAD+ levels have been linked to aging-associated pathologies. Here the authors present results of a double-blind, randomized crossover trial on 30 healthy middle-aged individuals to show that nicotinamide riboside effectively elevates NAD+ levels in humans, appears to be well tolerated, and may have potential to improve cardiovascular parameters. Introduction Advancing age is the primary risk factor for the development of cardiovascular disease (CVD), which remains the leading cause of morbidity and mortality in industrial and post-industrial societies 1 . The increase in CVD risk with aging is driven largely by adverse changes to arteries, including stiffening of the aorta, and by increases in systolic blood pressure 2 . As such, interventions designed to lower blood pressure and/or improve arterial function hold promise for preventing age-related CVD. Chronic calorie restriction (CR) prevents the development of arterial dysfunction and increases in blood pressure with aging in rodents 3 , 4 , and lowers arterial stiffness and blood pressure in overweight-obese middle-aged and older adults 5 , 6 . Despite numerous health benefits, adherence to chronic CR remains poor and possibly even unsafe in normal weight older adults 7 – 9 . As such, there is a critical need to establish safe, practical alternatives to regular CR for enhancing cardiovascular function and health with aging in humans 10 . The recent identification of several key molecular mechanisms responsible for CR-mediated longevity in model organisms has led to an exciting search for “CR-mimetic” interventions to improve cardiovascular and other physiological functions with aging 11 , 12 . In this regard, nicotinamide adenine dinucleotide (NAD+) has emerged as a critical signaling molecule and essential substrate for sirtuins, a class of enzymes that mediate several of the beneficial effects of CR in model organisms 13 , 14 , including the maintenance of cardiovascular function 15 . Moreover, CR has been shown to increase NAD+ levels in pre-clinical models 16 , 17 . The cellular bioavailability of NAD+ and related metabolites declines in animals and in humans during normal aging 13 , 18 – 21 and may contribute to physiological aging by reducing sirtuin activity. Although NAD+ can be synthesized de novo from the amino acid tryptophan, this process does not occur in all tissues, requiring most cells to rely on a salvage pathway for regenerating NAD+ from other intracellular intermediates, which are primarily made ava [...] for enzymes involved in the beneficial effects of regular calorie restriction on healthspan. As such, the use of NAD+ precursors to augment NAD+ bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging in humans. Here we provide the evidence in a 2 × 6-week randomized, double-blind, placebo-controlled, crossover clinical trial that chronic supplementation with the NAD+ precursor vitamin, nicotinamide riboside (NR), is well tolerated and effectively stimulates NAD+ metabolism in healthy middle-aged and older adults. Our results also provide initial insight into the effects of chronic NR supplementation on physiological function in humans, and suggest that, in particular, future clinical trials should further assess the potential benefits of NR for reducing blood pressure and arterial stiffness in this group. Declining NAD+ levels have been linked to aging-associated pathologies. Here the authors present results of a double-blind, randomized crossover trial on 30 healthy middle-aged individuals to show tha [...]